Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ITR Integra Resources	C$2.01	C$2.19	C$1.10 ▼ C$2.68	C$237.56M	1.37	425,474 shs	142,848 shs
NSR Neustar, Inc. Neustar, Inc. Cla	$7.76	$0.00	$21.10 ▼ $34.40	$477.94M	N/A	13,059 shs	N/A
PPTA Perpetua Resources	$15.45 +4.1%	$13.79	$5.25 ▼ $17.96	$1.60B	-0.04	1.11 million shs	2.51 million shs
SLS SELLAS Life Sciences Group	$1.92 +1.1%	$1.77	$0.77 ▼ $2.27	$191.58M	2.31	1.82 million shs	3.04 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ITR Integra Resources	-1.95%	-0.99%	-10.27%	-18.95%	+45.65%
NSR Neustar, Inc. Neustar, Inc. Cla	0.00%	0.00%	0.00%	0.00%	0.00%
PPTA Perpetua Resources	+1.23%	+16.21%	+15.58%	+11.16%	+128.31%
SLS SELLAS Life Sciences Group	-4.04%	-9.09%	+14.46%	+48.44%	+74.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ITR Integra Resources	1.8571 of 5 stars	3.5	0.0	0.0	0.0	1.4	2.5	0.0
NSR Neustar, Inc. Neustar, Inc. Cla	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PPTA Perpetua Resources	2.9329 of 5 stars	3.6	1.0	0.0	0.0	3.3	3.3	0.6
SLS SELLAS Life Sciences Group	0.3527 of 5 stars	0.0	1.0	0.0	0.0	2.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ITR Integra Resources	3.00	Buy	C$4.31	114.55% Upside
NSR Neustar, Inc. Neustar, Inc. Cla	0.00	N/A	N/A	N/A
PPTA Perpetua Resources	3.20	Buy	$21.17	37.00% Upside
SLS SELLAS Life Sciences Group	3.00	Buy	$7.00	264.58% Upside

Current Analyst Ratings Breakdown

Latest ITR, PPTA, NSR, and SLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	SLS SELLAS Life Sciences Group	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $7.00
6/18/2025	PPTA Perpetua Resources	National Bankshares Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/18/2025	PPTA Perpetua Resources	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $17.00
6/17/2025	PPTA Perpetua Resources	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.50
5/13/2025	PPTA Perpetua Resources	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.50
4/21/2025	ITR Integra Resources	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target		C$4.00 ➝ C$4.50

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ITR Integra Resources	N/A	N/A	C$0.59 per share	3.41	C$0.45 per share	N/A
NSR Neustar, Inc. Neustar, Inc. Cla	$27.15M	17.60	$0.19 per share	41.83	$4.72 per share	1.64
PPTA Perpetua Resources	N/A	N/A	N/A	N/A	$1.55 per share	N/A
SLS SELLAS Life Sciences Group	$1M	191.58	N/A	N/A	$0.13 per share	14.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ITR Integra Resources	-C$40.04M	-C$0.48	N/A	∞	N/A	N/A	-63.49%	-17.95%	N/A
NSR Neustar, Inc. Neustar, Inc. Cla	-$1.68M	$0.35	22.17	77.60	N/A	3.67%	-0.47%	-0.38%	N/A
PPTA Perpetua Resources	-$14.48M	-$0.29	N/A	N/A	N/A	N/A	-22.11%	-19.91%	8/8/2025 (Estimated)
SLS SELLAS Life Sciences Group	-$30.88M	-$0.38	N/A	N/A	N/A	N/A	-193.67%	-113.02%	8/12/2025 (Estimated)

Latest ITR, PPTA, NSR, and SLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	SLS SELLAS Life Sciences Group	-$0.0767	N/A	N/A	N/A	N/A	N/A
8/8/2025	N/A	PPTA Perpetua Resources	-$0.14	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	SLS SELLAS Life Sciences Group	-$0.1067	-$0.07	+$0.0367	-$0.07	N/A	N/A
5/9/2025	Q1 2025	PPTA Perpetua Resources	-$0.05	-$0.12	-$0.07	-$0.12	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ITR Integra Resources	N/A	N/A	N/A	N/A	N/A
NSR Neustar, Inc. Neustar, Inc. Cla	$0.16	2.06%	N/A	45.71%	N/A
PPTA Perpetua Resources	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ITR Integra Resources	35.54	0.82	1.49
NSR Neustar, Inc. Neustar, Inc. Cla	0.13	1.73	1.73
PPTA Perpetua Resources	N/A	5.95	5.95
SLS SELLAS Life Sciences Group	N/A	4.64	4.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ITR Integra Resources	26.52%
NSR Neustar, Inc. Neustar, Inc. Cla	1.49%
PPTA Perpetua Resources	70.07%
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
ITR Integra Resources	17.78%
NSR Neustar, Inc. Neustar, Inc. Cla	N/A
PPTA Perpetua Resources	1.90%
SLS SELLAS Life Sciences Group	1.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ITR Integra Resources	41	118.19 million	N/A	Not Optionable
NSR Neustar, Inc. Neustar, Inc. Cla	N/A	61.59 million	N/A	Not Optionable
PPTA Perpetua Resources	30	103.87 million	101.90 million	Optionable
SLS SELLAS Life Sciences Group	10	99.78 million	98.58 million	Not Optionable

ITR, PPTA, NSR, and SLS Headlines

Recent News About These Companies

SELLAS Life Sciences Group (NASDAQ:SLS) Price Target Raised to $7.00

3 hours ago | marketbeat.com

Sellas Flat on Trial Success

July 16 at 6:14 AM | baystreet.ca

SELLAS gains as mid-stage trial for leukemia drug succeeds

July 16 at 6:14 AM | msn.com

SELLAS Life Sciences Group Welcomes Dr. Linghua Wang to Scientific Advisory Board - Nasdaq

July 9, 2025 | nasdaq.com

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 3.7% - Here's What Happened

July 9, 2025 | marketbeat.com

Sellas Life Sciences appoints Linghua Wang to Scientific Advisory Board

July 7, 2025 | msn.com

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

July 7, 2025 | globenewswire.com

SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes

June 24, 2025 | finance.yahoo.com

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?

June 23, 2025 | zacks.com

Sellas Life Sciences: Tons Of Completed Studies

June 17, 2025 | seekingalpha.com

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Large Increase in Short Interest

June 16, 2025 | marketbeat.com

Nostrand Robert L. Van Purchases 10,000 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Stock

June 14, 2025 | insidertrades.com

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

June 5, 2025 | globenewswire.com

SELLAS Life Sciences Presents Preclinical Data on SLS009 as a Targeted Therapy for ASXL1 Mutated Colorectal Cancer at ASCO 2025

June 4, 2025 | nasdaq.com

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Director Jane Wasman Buys 20,000 Shares

June 3, 2025 | insidertrades.com

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

June 2, 2025 | globenewswire.com

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

May 20, 2025 | globenewswire.com

SELLAS Life Sciences Group, Inc. Common Stock

May 16, 2025 | fxempire.comF

Sellas doses first paediatric subject with AML in Phase II trial of SLS009

May 16, 2025 | msn.com

SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 15, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

ITR, PPTA, NSR, and SLS Company Descriptions

Integra Resources CVE:ITR

C$2.01 0.00 (0.00%)

As of 04:00 PM Eastern

Integra Resources Corp., a precious metals exploration and development company, engages in the acquisition, exploration, and development of mineral properties in the Great Basin of the Western United States. The company explores for gold and silver deposits. It primarily focuses on developing DeLamar Project located in southwestern Idaho; and the Wildcat and Mountain View Projects located in western Nevada. It also holds a portfolio of early-stage exploration projects in Idaho, Nevada, and Arizona. The company was formerly known as Mag Copper Limited and changed its name to Integra Resources Corp. in August 2017. Integra Resources Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.

Neustar, Inc. Neustar, Inc. Cla NYSE:NSR

NeuStar, Inc. is a global information services provider. The Company's cloud-based platforms and differentiated data sets offer informative, real-time analytics, which enable clients to make actionable, data-driven decisions. It provides chief marketing officers a suite of services to plan their media spends, identify and locate desired customers, invest in marketing campaigns, deliver relevant offers and measure the performance of these activities. Security professionals use the Company's solutions to maximize Web performance and protect against malicious attacks. It enables the exchange of essential operating information across multiple carriers to provision and manage services, assisting clients with order processing and routing of customer inquiries. The Company's services include marketing services, security services, data services and number portability administration center (NPAC) services.

Perpetua Resources NASDAQ:PPTA

$15.45 +0.61 (+4.11%)

Closing price 04:00 PM Eastern

Extended Trading

$15.26 -0.19 (-1.26%)

As of 05:53 PM Eastern

Perpetua Resources Corp. engages in the exploration and development of mineral properties in the United States. The company primarily explores for gold, silver, and antimony deposits. Its principal asset is the 100% owned Stibnite Gold project, which includes 1,672 unpatented lode claims, mill sites, and patented land holdings covering an area of approximately 11,548 hectares located in Valley County, Idaho. The company was formerly known as Midas Gold Corp. and changed its name to Perpetua Resources Corp. in February 2021. Perpetua Resources Corp. was incorporated in 2011 and is headquartered in Boise, Idaho.

SELLAS Life Sciences Group NASDAQ:SLS

$1.92 +0.02 (+1.05%)

Closing price 04:00 PM Eastern

Extended Trading

$1.93 +0.01 (+0.57%)

As of 05:55 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time